← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 306개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 100%임상시험 1620상태 APPROVED
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 164상태 RECRUITING
ADCSHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3
효능 ORR 85.5%임상시험 132상태 RECRUITING
AntibodyCHotBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 125상태 RECRUITING
AntibodyAHotstaleMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5
효능 ORR 93.5%임상시험 111상태 RECRUITING
ADCBHotBiologicstaleDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 69.7%임상시험 107상태 ACTIVE
AntibodyBHotstaleBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
ADCCBiologicstaleEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 40%임상시험 97상태 RECRUITING
AntibodyCstaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCCBiologicstaleNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 79상태 DISCONTINUED
ADCBBiologicstaleAmgensPhase 3

Sunitinib (Sunitinib)

Advanced Solid Tumors · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 78%임상시험 76상태 RECRUITING
ADCBiologicstaleHansoh BioMedical R&D Companyvedotin with pembrolizumabPhase 3

Cisplatin / carboplatin (Cisplatin / carboplatin)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 84%임상시험 67상태 RECRUITING
AntibodystaleShanghai Shengdi Pharmaceutical…vedotin (RC48) in combinati…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#인기#항체+5
임상시험 66상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCvedotin combined with pembr…Phase 2

Immune Checkpoint Inhibitor (Immune Checkpoint Inhibitor)

Unspecified Adult Solid Tumor, Protocol Specific · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 59%임상시험 66상태 RECRUITING
ADCBiologicstaleNovartis PharmaceuticalsPhase 2

Ribociclib (Ribociclib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · Breast Cancer

#BreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 66.7%임상시험 66상태 RECRUITING
ADCBiologicstaleDaiichi SankyoDM1) and trastuzumab deruxt…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Breast Cancer; HER2-positive Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 65.8%임상시험 66상태 RECRUITING
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
ADCBiologicstaleDaiichi SankyoreleasePhase 1

DP1 (DS-8201a, DS-8201a (DP1))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 64상태 ACTIVE

1 / 16 페이지

← 이전다음 →